US stocks climbed late Wednesday morning as investors cheered a major development in the fight against cancer and a move by the US Treasury to support the bond market. The rally was led by Moderna, whose shares soared 122.9% after the company and partner Merck reported encouraging trial data for a melanoma vaccine.
The news injected a strong dose of optimism into the market, pushing major indexes higher and overshadowing lingering concerns about inflation and interest rates. The Treasury's announcement that it would double the maximum size of certain long-dated bond buybacks starting September 9th further reinforced the upbeat mood.
Moderna's melanoma breakthrough
Moderna and Merck have been developing an experimental messenger RNA (mRNA) vaccine designed to treat melanoma, a serious form of skin cancer. The vaccine is personalized to each patient's tumor and works by training the immune system to recognize and attack cancer cells. The latest trial results showed significant improvement in survival outcomes, which investors saw as a potential game-changer for the company.
The 122.9% surge in Moderna's stock reflects the market's belief that this could be a multi-billion-dollar opportunity. It also validates the broader potential of mRNA technology beyond COVID-19, where Moderna first made its name. For a company that has seen its revenue decline sharply as pandemic demand faded, a successful cancer treatment could provide a new growth engine.
This is not the first time Moderna's cancer vaccine has shown promise, but the strength of the latest data has raised hopes that it could eventually reach the market. Analysts note that the path to approval is still long and uncertain, but the market is clearly pricing in a higher probability of success.
Treasury doubles long-dated bond buybacks
In a separate but related development, the US Treasury announced it would double the maximum size of its buybacks of long-dated bonds, starting September 9th. This is part of the Treasury's ongoing effort to manage the maturity profile of its debt and improve liquidity in the Treasury market.
Buybacks, also known as repurchases, allow the Treasury to retire older, less liquid bonds and replace them with newer, more actively traded issues. By increasing the size of these operations, the Treasury aims to reduce volatility in long-term yields, which have been a source of concern for investors. The 30-year Treasury yield has recently hovered near multi-decade highs, partly due to worries about government borrowing and inflation.
The move was seen as a signal that the Treasury is attentive to market conditions and willing to act to keep the bond market functioning smoothly. It also provided a boost to risk appetite, as investors interpreted it as a step to stabilize long-term borrowing costs.
What it means for investors
For everyday investors, the combination of a major biotech win and Treasury action creates a more favorable backdrop for stocks. The Moderna news is a reminder that innovation can drive outsized returns, but it also comes with high risk. Biotech stocks are notoriously volatile, and a single trial result can send shares soaring or plunging. Investors should be cautious about chasing such moves, as the long-term outcome is far from certain.
The Treasury's bond buyback expansion is more about the fixed-income market, but it has ripple effects. Lower volatility in long-term yields can help stabilize the stock market, particularly for growth and technology companies that are sensitive to interest rates. When yields rise, future earnings become less valuable, which tends to hurt growth stocks. By potentially keeping a lid on yields, the Treasury's move could support the broader market.
However, investors should keep in mind that the Treasury's action is not a change in monetary policy. The Federal Reserve still sets interest rates, and its decisions will continue to be the primary driver of market direction. The buyback program is a technical tool, not a stimulus measure.
Looking ahead, market participants will be watching for further updates on Moderna's melanoma vaccine and any additional Treasury announcements. The September 9th start date for the expanded buybacks is also on the calendar. For now, the mood is decidedly risk-on, but as always, investors should stay diversified and focus on their long-term goals.
